Core Laboratories N.V.
CLB · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $135 | $130 | $124 | $129 |
| % Growth | 3.4% | 5.3% | -4.4% | – |
| Cost of Goods Sold | $108 | $107 | $103 | $110 |
| Gross Profit | $26 | $23 | $20 | $19 |
| % Margin | 19.3% | 17.5% | 16.5% | 15% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $11 | $10 | $14 | $9 |
| SG&A Expenses | $11 | $10 | $14 | $9 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$6 | -$3 | $2 | -$4 |
| Operating Expenses | $5 | $7 | $16 | $5 |
| Operating Income | $21 | $15 | $4 | $14 |
| % Margin | 15.6% | 11.7% | 3.6% | 11% |
| Other Income/Exp. Net | -$3 | -$3 | -$3 | -$3 |
| Pre-Tax Income | $18 | $13 | $2 | $12 |
| Tax Expense | $4 | $2 | $2 | $4 |
| Net Income | $14 | $11 | -$0 | $7 |
| % Margin | 10.6% | 8.2% | -0.1% | 5.7% |
| EPS | 0.3 | 0.22 | -0.003 | 0.16 |
| % Growth | 36.4% | 6,766.7% | -102.1% | – |
| EPS Diluted | 0.3 | 0.22 | -0.003 | 0.16 |
| Weighted Avg Shares Out | 47 | 48 | 47 | 47 |
| Weighted Avg Shares Out Dil | 47 | 48 | 47 | 48 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $3 | $3 | $3 |
| Depreciation & Amortization | $4 | $7 | $4 | $4 |
| EBITDA | $25 | $23 | $8 | $18 |
| % Margin | 18.2% | 17.4% | 6.6% | 13.8% |